



JPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. : 10/803,187 Confirmation No. : 5120
First Named Inventor : Thomas CHRISTOPH
Filed : March 18, 2004
TC/A.U. : 1614
Examiner : Unassigned
Docket No. : 029310.53299US
Customer No. : 23911
Title : Combination of Selected Opioids with Muscarine
Antagonists for Treating Urinary Incontinence

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R §§ 1.97 AND 1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem relevant to patentability of the claims of the above-identified application.

STATEMENT OF RELEVANCE

The relevance of the references listed on the PTO 1449 as AJ, AK, AL, AM, AN, AO AP, AQ, and AR to the subject matter of the present invention is given in the specification of the present invention.


English abstracts are submitted herewith for the references listed on the PTO 1449 as AA, AB, and AD.

The present Information Disclosure Statement is being filed (1) no later than three months from the application's filing date or (2) before the mailing date of the first Office Action on the merits (whichever is later), and therefore no certification under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

Respectfully submitted,

March 30, 2005



J. D. Evans
Registration No. 26,269

CROWELL & MORING LLP
Intellectual Property Group
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 624-2500
Facsimile No.: (202) 628-8844
JDE:lck



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/803,187
		Filing Date	March 18, 2004
		First Named Inventor	Thomas CHRISTOPH
		Art Unit	1614
		Examiner Name	Unassigned
Sheet 1 of 2	Attorney Docket Number	029310.53299US	

FOREIGN PATENT DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	AA	DE 3129 982 A1	02/17/1983	JUTTA MEYER, ET AL.		AB
	AB	DE 40 41 559 A1	06/25/1992	BOEHRINGER INGELHEIM KG		AB
	AC	WO 96/27375 A2	09/12/1996	ALGOS PHARMACEUTICAL CORPORATION		
	AD	WO 01/24783 A2	04/12/2001	GRUENENTHAL GMBH		AB
	AE	WO 01/62236 A2	08/30/2001	PHARMACIA & UPJOHN COMPANY		
	AF	GB 857,194	12/29/1960	CLINICAL PRODUCTS LIMITED		

NON PATENT LITERATURE DOCUMENTS

Examiner Initial	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AG	A. DRAY, et al., Inhibition of Urinary Bladder Contractions by a Spinal Action of Morphine and other Opioids., The Journal of Pharmacology and Experimental Therapeutics, November 1984, pgs. 254-260, Vol. 231, No. 2, XP 000600400, USA	
	AH	CHRISTOPHER P. SMITH, et al., Genitourinary Tract Patent Update, Expert Opinion on Therapeutic Patents, 2000, pgs. 17-31, 11 (1), Ashley Publications Ltd., ISSN 1354-3776, XP-002223993	
	AI	JOHN A. BUTERA, et al., Recent Approaches to the Treatment of Urinary Incontinence: A Survey of Patent Activity from 1995 to 1998, Expert Opinion on Therapeutic Patents, 1998, pgs. 1017-1035, 8(8), Ashley Publications Ltd., ISSN 1354-3776, XP-002223992	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/803,187	
			Filing Date	March 18, 2004	
			First Named Inventor	Thomas CHRISTOPH	
			Art Unit	1614	
			Examiner Name	Unassigned	
Sheet	2	of	2	Attorney Docket Number	029310.53299US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AJ	K.-E. ANDERSSON, et al., The Pharmacological Treatment of Urinary Incontinence, BJU International, 1999, pgs. 923-947, 84	
	AK	J.-M. MALINOVSKY, MD., et al., The Urodynamic Effects of Intravenous Opioids and Ketoprofen in Humans, Anesth. Analg., 1998, , pgs. 456-461, 87, International Anesthesia Research Society	
	AL	P. T. DOYLE, et al., The Effects of Drugs and Anaesthetic Agents on the Urinary Bladder and Sphincters, British Journal of Urology, 1976, pgs. 329-335 48	
	AM	ISAO SHIMIZU, et al., Effects of (+)-Pentaocine and 1,3-Di-O-Tolylguanidine (DTG), Sigma (σ) Ligands, on Micturition in Anaesthetized Rats., British Journal of Pharmacology, 2000, pgs. 610-616, 131, Macmillan Publishers Ltd.	
	AN	ALAN J. WEIN, Pharmacologic Options for the Overactive Bladder, Urology 51 (Supplement 2A), February 1998, pgs. 43-47, Elsevier Science Inc.	
	AO	YUTAKA KIMURA, et al., Mechanisms of the Suppression of the Bladder Activity by Flavoxate, International Journal of Urology, pgs. 218-227 1996, 3	
	AP	DARRYL S. CHUTKA, et al., Urinary Incontinence in the Elderly, Drugs, Oct. 1998, pgs. 587-595, 56, (4), Adis International Limited	
	AQ	HITOSHI KOTANI, et al., A Study of Morphine-Induced Urinary Retention in Anesthetized Rats Capable of Micturition, Japan Journal of Pharmacology, 1988, pgs. 31-36, 48	
	AR	BENJAMIN DRENGER, MD., et al., Urodynamic Studies After Intrathecal Fentanyl and Buprenorphine in the Dog., Anesth. Analg., 1989, pgs. 348-353, 69, International Anesthesia Research Society	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.